Fresenius Kabi Deutschland GmbH

BELCANZI

Pharmaceutical preparations for human use, namely, preparations for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, endocrinological diseases and disorders, neurological diseases and disorders, metabolic diseases and disorders, rheumatological diseases and disorders, musculo-skeletal diseases and disorders;The wording BELCANZI has no meaning in a foreign language.;

BELCANZI

Pharmaceutical products for human use, namely products for the treatment of diseases and disorders of the immune system, inflammatory diseases and disorders, oncological diseases and disorders and viral infections;The word(s) BELCANZI has no meaning in a foreign language.;

BELCANZI

Pharmaceutical products for human use, namely, products for the treatment of diseases and disorders of the immune system, inflammatory diseases and disorders, oncological diseases and disorders and viral infections;The wording BELCANZI has no meaning in a foreign language.;

BIOSPECIALIZED

Printed materials, namely, training materials in the field of biosimilars, biologics, oncology, immunology, healthcare and medicine;BIO SPECIALIZED;

BIOSPECIALIZED

Providing online non-downloadable electronic publications in the nature of newsletter announcements in the field of biosimilars, biologics, oncology, immunology, healthcare and medicine;Downloadable electronic publications in the nature of training manuals in the field of biosimilars, biologics, oncology, immunology, healthcare and medicine; electronic downloadable publications, namely, training manuals in the field of biosimilars, biologics, oncology, immunology, healthcare and medicine; electronic publications, namely, brochures featuring healthcare information recorded on computer media;

BIOSPECIALIZED

Education and training, namely, providing classes, seminars, and workshops in the field of biosimilars and biological drug products for patients and families, industry and health care personnel, payer individuals, media and government advocacy groups; Education services in the nature of biosimilar and biological drug product manufacturing education, namely, providing classes, seminars, and workshops in the field of biosimilar and biological drug product manufacturing; Education services, namely, providing classes, seminars, and workshops in the field of biosimilar and biological drug product economics; Education and training services, namely, providing educational speakers in the field of biosimilar and biological drug products;BIO SPECIALIZED;Promoting awareness of biosimilars, oncology, immunology and medicine;Medical information services, namely, providing medical information;Product development; pharmaceutical product development;

CONVIO

Injection device for pharmaceutical preparations;

EMRIXBY

Pharmaceutical preparations for human use for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders;

EULADA

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections;

EZYGO

EASY GO;Injection device for pharmaceutical preparations not for use in general surgery or endoscopic surgery;

IDACIO

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections;

IDACIO

Pharmaceutical preparations for the treatment of autoimmune diseases, illnesses, and conditions;

IDACIO

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; Pharmaceutical preparations, namely, immunosuppressants; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, polyarticular juvenile idiopathic arthritis and active enthesitis related arthritis, Crohn's disease, ulcerative colitis, hidradenitis colitis, hidradenitis suppurativa and non-infectious uveitis; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Biologics, namely, biological preparations for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; Biologics, namely, biological preparations for the treatment of ankylosing spondylitis; Biological preparations for the treatment of and reducing signs and symptoms in adult patients with active ankylosing spondylitis; Protein therapeutics, namely, protein supplements; Pharmaceutical preparations for treating ankylosing spondylitis; Pharmaceutical preparations for the treatment of and for reducing signs and symptoms in adult patients with active ankylosing spondylitis; Pharmaceutical preparations for treating a wide variety of autoimmune diseases, illnesses and conditions;Protein for industrial use; Protein in raw material form for scientific and medical research; Protein for use in manufacture; Proteins for use in the manufacture of food supplements;On body medical device for dispensing a wide variety of pharmaceutical products in the nature of implantable drug delivery pumps; on body medical injection instrument for dispensing pharmaceuticals; on body medical device for administering drugs; on body injection device for pharmaceuticals;

IMMUGO

IMMUNE GO;Injection device for pharmaceutical preparations;

INCRAMOV

Pharmaceutical preparations for human use, namely, preparations for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, endocrinological diseases and disorders, neurological diseases and disorders, metabolic diseases and disorders, rheumatological diseases and disorders;The wording INCRAMOV has no meaning in a foreign language.;

INCRAMOV

Pharmaceutical preparations for human use, namely, preparations for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections;The wording INCRAMOV has no meaning in a foreign language.;

ITUOZO

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections, as well as treatment of CAR T-cell induced cytokine release syndrome;

KROMEYA

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections;

ONMIGO

ON ME GO;Injection device for pharmaceutical preparations;

ONTEEO

pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; pharmaceutical preparations for the treatment of CAR T-cell induced cytokine release syndrome;

ONTEEYA

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; pharmaceutical preparations for the treatment of CAR T-cell induced cytokine release syndrome;

ONTEEYO

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; pharmaceutical preparations for the treatment of CAR T-cell induced cytokine release syndrome;

ONTEYA

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; pharmaceutical preparations for the treatment of CAR T-cell induced cytokine release syndrome;

PULSIME

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections;

PULSIME

Pharmaceutical preparations for human use;

REMBURT

In the statement, Column 1, lines 4-6, Pharmaceutical preprations for human use, namely, preparations for the treatment of immunological, inflammatory and oncological diseases and disorders, and viral infections is deleted, and Pharmaceutical preprations for human use for the treatment of Systemic Lupus Erythematosus (SLE), rheumatoid arthritis, osteroarthritis, cartilage injury, and infertility diseases and disorders, excluding Parkinson and Alzheimer's diseases is inserted.;[ Pharmaceutical preprations for human use, namely, preparations for the treatment of immunological, inflammatory and oncological diseases and disorders, and viral infections ] * Pharmaceutical preprations for human use for the treatment of Systemic Lupus Erythematosus (SLE), rheumatoid arthritis, osteroarthritis, cartilage injury, and infertility diseases and disorders, excluding Parkinson and Alzheimer's diseases *;

RITKEBY

Pharmaceutical preparations for human use for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders;

ROMZURTO

Pharmaceutical preparations for human use, namely, preparations for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, endocrinological diseases and disorders, neurological diseases and disorders, metabolic diseases and disorders, rheumatological diseases and disorders;The wording ROMZURTO has no meaning in a foreign language.;

RYOPTIM

Pharmaceutical preparations for human use for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders;

RYTOKI

Pharmaceutical preparations for human use for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders;

RYZATUX

Pharmaceutical preparations for human use for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders;

RYZUMTRA

Pharmaceutical preparations for human use for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders;

SIMILAR WHERE IT COUNTS, DIFFERENT WHERE IT MATTERS

Providing online non-downloadable electronic publications in the nature of newsletter announcements in the field of biosimilars, biologics, oncology, immunology, healthcare and medicine; Education and training, namely, providing classes, seminars, and workshops in the field of biosimilars and biological drug products for patients and families, industry and health care personnel, payer individuals, media and government advocacy groups; Education services in the nature of biosimilar and biological drug product manufacturing education, namely, providing classes, seminars, and workshops in the field of biosimilar and biological drug product manufacturing; Education services, namely, providing classes, seminars, and workshops in the field of biosimilar and biological drug product economics; Education and training services, namely, providing educational speakers in the field of biosimilar and biological drug products;Downloadable electronic publications in the nature of training manuals in the field of biosimilars, biologics, oncology, immunology, healthcare and medicine; electronic downloadable publications, namely, training manuals in the field of biosimilars, biologics, oncology, immunology, healthcare and medicine; electronic publications, namely, brochures featuring healthcare information recorded on computer media;Printed materials, namely, training materials in the field of biosimilars, biologics, oncology, immunology, healthcare and medicine;Promoting awareness of biosimilars, oncology, immunology and medicine;Medical information services, namely, providing medical information;Product development; pharmaceutical product development;

STIMUFEND

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections;

STIMUFEND

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections;

TILMIUS

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections, excluding pharmaceutical preparations for the treatment of osteoporosis and the prevention of fractures resulting from osteoporosis; pharmaceutical preparations for the treatment of CAR T-cell induced cytokine release syndrome, excluding pharmaceutical preparations for the treatment of osteoporosis and the prevention of fractures resulting from osteoporosis;

TIVMA

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections;

TOCIMIUS

pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; pharmaceutical preparations for the treatment of CAR T-cell induced cytokine release syndrome;The wording TOCIMIUS has no meaning in a foreign language.;

TOCYMA

Pharmaceutical preparations for human use for the treatment of immunological diseases and disorders, inflammatory diseases and disorders including giant cell arteritis (GCA), oncological diseases and disorders and viral infections, as well as treatment of CAR T-cell induced cytokine release syndrome;

TYENNE

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; pharmaceutical preparations for the treatment of CAR T-cell induced cytokine release syndrome;

WISOM

Pharmaceutical preparations for human use, namely preparations for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, endocrinological diseases and disorders, metabolic diseases and disorders, rheumatological diseases and disorders, musculo-skeletal diseases and disorders;The wording WISOM has no meaning in a foreign language.;

XAMPENSO

Pharmaceutical preparations for human use, namely, preparations for the treatment of immunological, inflammatory and oncological diseases and disorders and viral infections;

XAMPENSO

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; pharmaceutical preparations for the treatment of CAR T-cell induced cytokine release syndrome;

XUPOSY

Pharmaceutical preparations for human use for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders;

ZIMRIXBY

Pharmaceutical preparations for human use for the treatment of immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders;

ZIPATICO

Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections, as well as for the treatment of CAR T-cell induced cytokine release syndrome;